Hideko Isozaki, Ph.D.

post-doctoral

Hideko joined the Hata Lab in June 2017. She completed Ph.D. at Okayama University in the Department of Hematology, Oncology and Respiratory Medicine where she focused on the mechanisms of drug resistance to molecularly target inhibitor in lung cancer harboring the EML4-ALK fusion gene. A number of mechanisms of drug resistance to target therapy have been identified such as her previous study, yet little is know what’s happening on during a course of treatment. She currently interested in how cancer cells evolve from drug tolerant persister status and acquire the resistance in non-small cell lung cancer with EGFR mutations or ALK rearrangements. To define the mechanisms of cancer evolution during target therapy, she is excitedly exploring the linkage pathway between innate immune response and genomic instability. This project will lead to prevent acquired drug resistance and provide new therapeutic strategies. Outside the lab, Hideko’s favorite things are playing kyudo (archery) and piano.